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The passive serum  therapy of experimental and  clinical tumors,  while frequently 
attempted,  has  met  with  only  very  limited  success  (1).  The  elegant  techniques  of 
K~Jhler and Milstein (2), enabling the production of virtually unlimited amounts of 
homogeneous antibody, have led to a  reconsideration of passive antibody treatment 
for  malignant  disease.  This  interest  is  based  on  the  possibility  that  the  use  of 
monoclonal antibodies may be successful where serum  was  unsuccessful because  (a) 
insufficient  amounts  of,  or  low  titer  serum  was  used;  (b)  antibody  of  ineffective 
isotype(s) was predominant;  (c)  the antibody was of low avidity; or (d)  the antibody 
was of inappropriate specificity. 
Monoclonal  antibodies suitable  for  treatment  would  ideally be  those  specifically 
reactive with tumor cell surfaces.  Since the search for true tumor-specific antibodies 
has been  unsuccessful, an alternative approach has been taken using antibodies that 
are reactive with malignant and normal cells but  that  are not  lethal or significantly 
toxic to the recipients (3-16). With this approach, we have been able to use monoclonal 
antibodies successfully against a  normal murine differentiation antigen for the treat- 
ment  of a  transplanted T  cell leukemia.  Specifically, monoclonal  antibodies against 
the Thy-I. 1 differentiation antigen induced prolonged survival and cured a significant 
proportion of treated animals challenged with syngeneic AKR/J  SL2 leukemia cells 
(4).  In  those  studies,  a  comparison  of antibodies of the  immunoglobulin  M  (IgM), 
IgG~,, and IgG3 isotypes demonstrated that the IgG2~ antibody was most effective and 
the lgM antibody ineffective. In the present study, we further examined the antitumor 
activity of the  IgG2a anti-Thy-l.1  monoclonal  antibody.  We  found  that  antibody 
therapy  could  consistently  eliminate  up  to  3  ×  l0  s  transplanted  syngeneic  SL2 
leukemia, and identified factors which  limited the effectiveness of antibody. Specifi- 
cally, metastatic disease resulted from the growth of Thy-1.1-negative leukemic cells, 
whereas  development  of a  solid  tumor  nodule  at  the  inoculum  site  resulted  from 
failure of the host to eliminate anti-Thy-1.1  antibody-coated tumor cells. 
Materials and  Methods 
Mice and Leukemias.  AKR/J mice were obtained from The Jackson Laboratory, Bar Harbor, 
ME. The transplantable AKR/J SL2 leukemia was derived from a spontaneous thymoma in 
an AKR mouse  (17).  The SL2 cells were maintained in  vitro and  in vivo by intraperitoneal 
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inoculation of leukemic spleen cells. SL2 cells express high concentrations of Thy-1.1  both in 
vivo and in vitro. Tumors were implanted as single-cell suspensions of in vivo passaged cells 
given  subcutaneously  in  a  volume  of 0.1  ml.  The  TD~  and  TDlm  for  SL2  implanted 
subcutaneously in AKR/J mice are 102 and  104 cells, respectively (data not shown). 
Monoclonal Anti-Thy-l.l  Antibody.  The generation and characterization of the IgG2, mono- 
clonal anti-Thy-1.1 antibody designated 19-E12 have been previously described (3, 4). Hybrid 
cells secreting 19-E 12 antibody were inoculated intraperitoneally into pristane-primed syngeneic 
(129  ×  BALB/c)FI mice for the production of ascites fluid. The ascites fluid was cytotoxic in 
the presence of rabbit serum as a source of complement against Thy-1.1 + AKR/J thymocytes 
and  SL2  leukemic cells, but  not  against Thy-l.2  + AKR/Cu  thymocytes or AKR/Cu  SLI 
leukemic cells (titer <10-2).  19-E12 was also active in antibody-dependent cellular cytotoxicity 
with a titer of 5 ×  10  -5 using C57B1/6 spleen cells (20% lysis end point) (4). The concentration 
of IgG in the ascites fluid was assayed by a solid-phase radioimmune assay (18). Briefly, rabbit 
anti-mouse IgG was fixed to wells ofa microtiter plate and the concentration of 19-E12 ascites 
•  i  125  fluid that produced 50% inhibition of the bind ng of  I-labeled 19-E12 (purified by adsorption 
and elution from staph A [19]) to the anti-mouse IgG was compared with the concentration of 
a  standard preparation of purified unlabeled  19-E12  (calculated from the absorbance at 280 
E1 ....  of  14)  that  produced  equivalent  inhibition.  nm  assuming  an  extinction  coefficient,  1% 
Antibody was administered as unpurified pooled ascites adjusted to a complement-dependent 
cytotoxic titer against SL2 leukemic cells of 10 -° (50% lysis end point). The pooled, adjusted 
ascites contained ~4 mg/ml IgG. 
Antibody was purified for therapy studies by adsorption and elution from a Staphylococcus 
protein  A-Sepharose affinity column  (Pharmacia  Fine Chemicals,  Uppsala,  Sweden)  (19). 
Column eluates were concentrated and diafiltered in phosphate-buffered saline (PBS) 1 using a 
PM-10 membrane (Amicon Corp., Lexington, MA). The concentrate contained 42 mg/ml of 
antibody and had a cytotoxic titer (50% lysis end point) against ~lCr-labeled SL2 leukemia cells 
of 2 ×  10 -v. The concentrated antibody was diluted in PBS and administered in volumes of 
200-400 #1. 
Other  Antibodies.  Fluorescein-conjugated  19-E12,  monoclonal  anti-H-H-2  k antibody, and 
fluorescein-conjugated anti-IgG2a antibody were kindly provided by Dr. J. Ledbetter (Genetic 
Systems  Inc.,  Seattle, WA).  Monoclonal  antibody  10.2,  an  IgG2,  directed against  human 
lymphocytes, was kindly provided by Dr.  P.  Martin  and  Dr. J.  Hansen  (Fred Hutchinson 
Cancer Research Center).  10.2 was not cytotoxic to AKR/J thymocytes, SL2, or SL1  ceils. 
Monoctonal murine anti-AKR-MuLV gp70 antibody 16B7 (20) and anti-Thy-1.1 alloantiserum 
(AKR/Cu anti-AKR/J) were kindly provided by Dr. R. Nowinski (Genetic Systems Inc.). 
Immunofluorescence Studies.  Tissue samples were minced in  RPMI  1640 supplemented with 
5%  fetal calf serum  (5%  RPMI)  and  filtered through  40-/Lm nylon  mesh.  Viable cells were 
isolated on a Ficoll-Hypaque density gradient (A --- 1.090) and washed in 5% RPMI. Single-cell 
suspensions were incubated for 30 rain with antibody-containing ascites fluid (at a  1:1,000 final 
dilution) or fluorescein-conjugated antibody in 5% RPMI at room temperature. The cells were 
then washed and, in indirect immunofluorescence studies, incubated with a  1:40 dilution of an 
affinity-purified fluorescein-labeled  rabbit anti-mouse IgG or IgM serum (Bionetics Laboratory 
Products, Litton Bionetics Inc., Kensington, MD) for 30 min on ice. Cells were examined by 
flow microfluorometry using the FACS II system  (B-D FACS Systems, Becton, Dickinson & 
Co., Sunnyvale, CA) at a rate of 103 cells/s. 
Results 
We have previously demonstrated that  the growth of a  subcutaneous  inoculum of 
1-3  ×  l0  s  syngeneic  SL2  leukemia  cells  could  be  prevented  by  the  infusion  of 
monoclonal  IgG2a  anti-Thy-l.1  antibody  (4).  The  treatment  regimen  used  was  an 
arbitr~try one  consisting of  100/~1  of ascites fluid containing anti-Thy-l.1  antibody 
given intravenously 1-2 h  after the tumor was inoculated. This was followed by three 
or more doses of 50/~1  i.p. given at  3-4 d  intervals. The following experiments were 
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TABLE  I 
Relationship of Antibody Dose and Antitumor Effects 
Ascites fluid 
dose (rag anti- 
body) 
Experiment 
I  II  lII  IV 
Total 
% 
0  0/5  0/5  0/4  0/5  0/19 (0) 
0.4  4/5  1/5  --  2/5  7/15 (47) 
1.2  t/5  015  415  015  5120 (25) 
3.2  5/5)  5/5  I/4  4/4  15/18 (83) 
6.4  --  --  2/4  0/5  2/9  (22) 
The ability of increasing doses of ascites fluid containing 19-EI2 antibody to inhibit the growth of 3 X l0  s 
SL2 leukemic cells implanted subcutaneously in AKR/J  mice was determined. 1-2 h after tumor cell 
inoculation, doses of ascites fluid (4 mg antibody/ml) containing 0.4, 1.2, 3.2, or 6.4 mg of antibody were 
infused via the  retroorbital venous plexus. The number  of animals surviving tumor-free >90  d  and 
considered cured (numerator), and the number of animals treated (denominator) is shown for each of four 
experiments. 
designed to determine the maximal anti-leukemia effect that could be achieved using 
monoclonal anti-Thy-1.1 antibody. First we examined the relationship of the dose of 
antibody infused and the number of subcutaneous leukemia cells that were eliminated, 
as well as the maximal number of leukemic cells that could be eliminated. Second, 
the effect of multiple vs. single doses of antibody was determined. 
Relationship of Anti-leukemic Effect and Antibody Dose.  To quantitate the anti-leukemic 
effect  of monoclonal anti-Thy-l.1 antibody, we  examined the  ability of increasing 
amounts of antibody infused as  a  single, intravenous bolus to  prevent leukemia in 
mice challenged with increasing doses of tumor cells. Specifically, AKR/J  mice were 
challenged subcutaneously with  3  ×  10  a,  10 6,  or  3  X  10 6  SL2  leukemia cells.  1-2  h 
later, groups of these mice were treated by an intravenous infusion of 100,  300, 800, 
or  1,600  /zl  of ascites  fluid  containing 4  mg/ml  19-El2  anti-Thy-l.1  monoclonal 
antibody (see Materials and Methods). 
The results demonstrated that  a  significant proportion of mice challenged with 3 
X  10  '5 SL2 cells could be cured by a single dose of antibody (Table I). A portion of the 
mice treated with each antibody dose was cured, with the highest and most consistent 
rate  (83%)  seen  in  mice  treated  with  ascites  fluid containing 3.2  mg  of antibody. 
Although a  strict dose relationship was  not observed in each experiment, lesser but 
significant effects were usually seen in mice treated with lower doses of 0.4 or  1.2 mg 
(cure rates of 47 and 25%, respectively). At the highest dose tested  (6.4 mg antibody 
contained in  1,600 btl ascites fluid) only a  22% cure rate was achieved.  Because the 
decreased effectiveness of the highest dose of ascites fluid tested may have been due 
to the infusion of material other than antibody, the effectiveness of 19-E12 antibody 
purified  by  adsorption  and  elution  from  Staphylococcus  protein  A  was  tested. 
Treatment of mice  with  1.5  mg  purified  antibody led  to  the  inhibition of tumor 
growth in four of five mice, whereas the infusion of higher doses of antibody led to a 
lower cure rate. All mice treated with  16 mg developed leukemia (Table II). Similar 
results  were  obtained  in  a  second  experiment.  To  determine  whether  variability 
between animals in each treatment group was due to the faulty injection of antibody, 
serum was obtained from each mouse 24 h  after the infusion of antibody and tested 
for  cytotoxicity.  Within  each  dosage  group  there  was  relatively  uniform  serum BADGER AND BERNSTEIN  831 
TABLE  II 
Antitumor Effects of Purified Antibody 
Number cured/Number 
Antibody dose  treated  Cytotoxic titer  -~ (mean +- SD) X 10  a 
mg 
0  0/5  <0.1 
0.5  3/5  1.2 ±  0.4 
1.5  4/5  10.0 ±  2.4 
8  2/5  66.8 ±  3.8 
16  0/5  188.8 ±  39.6 
3 X tO  5 SL2 leukemic cells were implanted subcutaneously in AKR/J mice.  1 h later antibody purified by 
adsorption and elution from Staphylococcus  protein A (see Materials and Methods)  was infused  via the 
retroorbital  venous  plexus.  The number  of animals surviving tumor-free at  50  d  (numerator)  and  the 
number of animals treated (denominator) is shown for each treatment group. Serum samples were obtained 
24 h after the infusion of purified 19-E12 antibody and complement-dependent cytotoxic titers (50% lysis) 
against  SL2 leukemic cells determined using a ~]Cr-release assay. Mean titer ± SD is shown for each group. 
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FIG.  1.  Determination  of maximal  antitumor  effect  of antibody  therapy.  AKR/J  mice were 
challenged subcutaneously  with 3 ×  105 (left),  106 (middle),  or 3 X  106 (right)  SL2 leukemic cells. 
1-2 h later groups  of 4-6 mice were treated with an intravenous dose of ascites fluid containing 0 
(  ), 0.4 (-.-),  1.2 (.....), 3.2 (  ), or 6.4 (- - -) mg 19-E12 antibody. Upper and lower panels 
are two separate experiments. 
cytotoxic activity (Table II). Furthermore, there were no differences in serum cytotoxic 
titer  within  each  group  between  those  animals  that  developed  leukemia  and  those 
that  did  not  (data  not  shown).  This  result  suggested  that  the  consistently  observed 
differences within treatment  groups  may be caused by host factors. 
The maximal number of tumor cells that could be eliminated by antibody treatment 
was also determined.  In these experiments, antibody doses found effective in prevent- 
ing leukemia due to inocula of 3  ×  105 SL2 leukemic cells were tested for their ability 
to prevent  the outgrowth  of larger tumor  doses.  The  results showed  that  infusion  of 
amounts  of ascites fluid containing 0.4-6.4 mg  19-E 12 antibody  inhibited the growth 
of inocula consisting of 3  X  10  ~ SL2 leukemic cells and  in some instances of 106 cells, 
but  each  dose  level failed  to  cure  any  mice challenged  with  3  ×  l0  G leukemic  cells 
(Fig.  1). We also determined whether the growth of an increased number  of leukemic 
cells could be inhibited using purified antibody. In two studies, no cures were obtained 832  MONOCLONAL  ANTIBODY THERAPY OF MURINE LEUKEMIA 
after challenge with  106 or 3  X  106 cells when groups of five mice each were treated 
with  purified  antibody using  doses of 4,  8, or  16  mg per  animal  (data  not  shown). 
Thus,  the maximal  anti-leukemic  effect that  could  be consistently  achieved  using a 
single  bolus  of up  to  16  mg  of antibody  was  the  elimination  of 3  X  l0  s  cells. 
Furthermore,  the few mice cured after challenge with  106 leukemic cells  (4/67  in all 
experiments)  were cured  by lower antibody  doses  (0.4  and  1.2  rag).  This  lack of a 
dose-effect  relationship  suggests  that  106  cells  was  the  limiting  dose  curable  by 
antibody because of factors other than  antibody dose, e.g., participating  host factors 
(see Discussion). 
An analysis of the survival patterns of mice not cured of their tumors also revealed 
that the median survival for groups of antibody-treated mice challenged with a given 
tumor dose was essentially  the same whether  they were treated  with 0.4,  1.2,  3.2, or 
6.4 mg of antibody  (Fig.  1).  Thus,  death,  which  resulted  from metastatic  disease  in 
these  mice,  was  equally  delayed  by lower  as well  as  higher  doses of antibody.  The 
basis for this phenomenon is explored in later experiments that examine the reactions 
of the  metastatic  leukemic  cells  with  19-E12  antibody.  Of further  interest  is  the 
observation  that  the  solid  tumor  that  grew  at  the  inoculum  site  often  became 
significantly  larger  before  death  in  the  majority  of treated  mice as  compared  with 
untreated  mice (data not shown). This was not a  result  of more rapid tumor growth 
in  treated  mice,  because  the  appearance  of a  palpable  nodule  was  delayed  only 
slightly  and  because  once  a  nodule  was  palpable  the  growth  rate  was  similar  in 
treated  and  untreated  animals.  Rather,  it  was  due  to the  continued  growth  during 
the period of extended survival that resulted  from the antibody treatment. 
Therapeutic  Effects of Single w. Multiple Antibody Doses.  We next determined whether 
there  was  an  advantage  in  infusing  multiple  antibody  doses.  For  this  purpose,  we 
compared the effects of a  relatively high dose of 19-E12 antibody (3.6 mg) given as a 
single  intravenous  infusion  on  day 0  vs.  a  3.6  i.v.  dose  on  day  0  followed  by  four 
additional  1.8  mg doses  given  intraperitoneally  every  3-4  d.  These  schedules  were 
also compared  with  a  regimen  similar  to  that  used  in  previous studies,  i.e.,  0.4  mg 
given intravenously on day 0 followed by four doses of 0.2 mg i.p. every 3-4 d. These 
regimens were used  to treat  mice challenged  with  3  ×  105 or 3  ×  106 SL2 leukemic 
cells given subcutaneously. The results  (Fig. 2)  revealed a significant antitumor effect 
from 3.6 mg of antibody but no additional benefit from the subsequent  1.8-rag doses. 
Further,  treatment  with a  single 3.6-rag dose was more effective than treatment  with 
0.4 mg followed by 0.2 mg in  mice challenged with  3  X  l0  s cells.  When  mice were 
challenged with  3  X  106 cells  there were no cures and survival was again prolonged 
to  the  same  extent  by  all  antibody  regimens.  Thus,  the  infusion  of a  single  high 
amount of antibody on the day of tumor inoculation  led to the maximal  antitumor 
effect that could be achieved, i.e., the inhibition of tumor growth due to 3 ×  105 cells. 
The failure of antibody to consistently eliminate >3  ×  105 cells at a  subcutaneous 
site  could  have  resulted  from either  the  lack of access  of antibody  to  the  tumor,  a 
failure  to eliminate  antibody-coated  tumor cells,  or the  escape of Thy-l.l-negative 
tumor cells. In the following experiments each of these issues was examined. 
Ability  of Antibody  to  Bind to  Tumor  Cells  Within  a  Subcutaneous  Nodule.  Binding  of 
infused  anti-Thy-l.1  antibody  to  subcutaneous  tumor  cells  in  vivo  was  directly 
examined using quantitative immunofluorescent techniques. For this purpose 3 X  106 
tumor cells were inoculated subcutaneously and, when a  palpable tumor nodule was BADGER  AND  BERNSTEIN  833 
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FIG. 2.  Antitumor effect of multiple vs. single antibody doses. Groups of five AKR/J mice each 
were implanted subcutaneously with 3 X 105 (top) or 3 ×  106 (bottom) SL2 leukemic cells. 1-2 h 
later, mice were treated with ascites fluid containing 4 mg/ml 19-E12 antibody. Treatment regimens 
were (a) no antibody (-  -), (b) a single intravenous dose of 3.6 mg(  ), (c) 3.6 mg i.v. on day 0 
followed by 1.8 mg i.p. on days 3, 7, 11, and 14 (-.-), (d) 0.4 mg i.v. on day 0 followed by 0.2 mg 
i.p. on days 3, 7, 11, and 14 (.....). 
present  (10-ram average diam), ascites fluid containing 19-E12 antibody was infused 
intravenously.  At  various times thereafter,  the  tumor  nodules were  removed  and  a 
single-cell suspension  was  obtained.  The  cell  surfaces  were  then  examined  for  the 
presence of the infused antibody by staining cells with  fluorescein-conjugated anti- 
mouse IgG antibody. The  amount  of fluorescence obtained was compared with  the 
maximum  amount  that  could be achieved if all available Thy-t.1  cell surface sites 
were coated with antibody. For this purpose, aliquots of the tumor cells were incubated 
in vitro with excess  19-E12  antibody before incubation  with  the fluorescein isothio- 
cyanate (FITC)-anti-mouse IgG antibody. A  third aliquot of cells was incubated with 
FITC-anti-IgM to determine nonspecific fluorescent binding. After incubation, cells 
were examined by flow microfluorometry using the FACS-II, and the location of the 
fluorescence histogram  peaks was  determined.  Thus,  the  proportion of cell surface 
Thy- 1.1 sites that were coated in vivo with the infused IgG antibody (percent in vivo 
saturation) could be determined from the histograms according to the formula: 
[Peak anti-IgG-FITC] -  [Peak anti-IgM-FITC] 
X  100. 
[Peak (in vitro  19-E12  +  anti-IgG-FITC)] -  [Peak anti-IgM-FITC] 
We first examined the specificity and time course of antibody binding.  100/B  of 
ascites fluid containing 0.4 mg 19-E12 antibody or, as a control, an equivalent amount 
of antibody of the same isotype but irrelevant specificity (antibody 10.2)  was infused 
intravenously. Tumor  nodules from  five to seven  individual mice were then  excised 
and examined at  12, 24, and 48 h  after antibody infusion (Fig. 3). Binding of 19-E12 
was maximal at 24 h  with  12 +  3% (mean +  SE) of the available Thy-l.1 sites coated 
with IgG antibody at  12 h, 39 +_ 7% at 24 h, and  18 +_ 2% at 48 h. The binding was 834  MONOCLONAL  ANTIBODY  THERAPY  OF  MURINE  LEUKEMIA 
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F[o.  3.  Kinetics of in vivo antibody binding to tumor cell  surfaces. AKR/J  /nice with palpable 
SL2 subcutaneous tumor nodules (0.5-1.0 cm diameter) were given intravenous infusions of ascites 
fluids containing 100 #1 0.4 mg 19-E12 or 10.2 (an IgG2~ antibody of irrelevant specificity) antibody 
12, 24, or 48 h  before analysis. Excised nodules were minced and viable cells isolated on a  Ficoll- 
Hypaque density gradient (A =  1.090).  Cells were then tested by indirect immunofluorescence after 
incubation with (a) FITC-rabbit anti-mouse IgG (to determine antibody bound in vivo); (b)  19-E12 
ascites fluid (1:1,000 dilution) and FITC-rabbit anti-mouse IgG (to determine the maximal amount 
of anti-Tby-l.l  antibody  that  can  bind  to  the  cell  surface);  or  (c)  FITC  rabbit  anti-IgM  (to 
determine nonspecific binding). Fluorescence was analysed with the FACS-II and a  composite of 
representative fluorescence histograms is shown. Not  shown is that  light scatter (size)  patterns in 
each case demonstrated that a  uniform cell population was being analysed. Furthermore, location 
of control FITC-anti-IgG fluorescence peaks with cells from untreated animals were always within 
10% of FITC anti-IgM peaks and at least two orders of magnitude less than  19-E12 +  FIT(] anti- 
IgG, peaks. 
specific, since IgG was not detected on tumor cells from mice treated with the control 
antibody. 
We next determined the relationship of antibody dose and the amount of antibody 
bound to the tumor cell surfaces. Animals with tumor nodules received 0.4,  1.2, or 3.2 
mg of 19-E 12 intravenously and ceils from the nodules were examined 24 h later. The 
proportion of available Thy-1.l sites  coated in vivo by antibody (percent saturation) 
was  found to increase when  larger amounts of antibody were infused.  Specifically, 
infusion of 0.4 mg led to the coating of 27 +  13%  (mean _+ SE) of available Thy-l.! 
sites,  1.2 nag to 51 _+ 5% saturation, and 3.2 mg to complete saturation. Moreover, 24 
h after antibody infusion, a linear relationship between the log of the serum comple- 
ment-dependent cytotoxic titer against  SL2 leukemic cells  in  vitro  (as  a  measure of 
unbound  anti-Thy-1.1  antibody  in  serum)  and  tumor  cell  surface  antibody  was 
observed (Fig. 4). Thus, antibody saturation of tumor cell surface antigenic sites could 
be  accurately predicted  from  the  analysis of free serum  antibody content.  Further, 
only the presence of very high amounts of antibody in the serum  (titer _>  10  -5 after 
infusion of 3.2 nag of antibody) led to sufficient infiltration of the subcutaneous space 
by the infused antibody to achieve maximal cell surface binding. 
Antigenic Nature of Transplanted Leukemia Cells that Escape Antibody Therapy. Because the 
infused antibody was capable of binding to tumor cells in the subcutaneous space and 
saturating  surface  antigenic  sites,  we  examined  whether  the  failure  of antibody 
therapy to eliminate >3 X  105 cells was a result of the failure of the host to eliminate 
antibody-coated cells  or of alterations in expression of the target Thy- 1.1  antigen by 
the leukemic cells. For this purpose, mice were challenged with 3 X  106 SL2 leukemic 
cells and,  1-2 h  later, received an intravenous infusion of ascites fluid containing 3.6 BADGER  AND BERNSTEIN  835 
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FIG. 4.  In vivo binding ofanti-Thy-1.1  antibody to subcutaneous leukemic cells: relationship with 
antibody dose. AKR/J mice with palpable subcutaneous SL2 tumor nodules were treated intrave- 
nously with doses of ascites fluid containing 0.4, 1.2, or 3.2 mg of 19-E12 antibody. 24 h later the 
nodule was excised and the amount  of infused antibody bound to the leukemic cell surfaces was 
determined by quantitative immunofluorescence (see text). The serum cytotoxic titer at the time of 
nodule  excision was determined  by a  complement-dependent  51Cr-release assay  (50% lysis end 
point). 
mg 19-E12 antibody, followed by intraperitoneal injections of 1.8 mg on days 3, 7,  10, 
and  14.  12 d after the last antibody dose, when the treated mice had developed tumor 
nodules at the inoculum site and enlarged spleens, they were killed and leukemic cells 
from  their  spleens  and  subcutaneous  nodules  were  obtained.  As  in  the  previous 
experiments, the amount  of cell surface IgG was determined by direct immunofluo- 
rescence using fluorescein-conjugated anti-mouse IgG antibody, and the expression of 
the target Thy-1.1 antigen was determined by indirect immunofluorescence using 19- 
E12 followed by the fluoresceinated anti-Ig reagent. 
Evaluation of leukemic cells from the nodules of five treated mice revealed that the 
cell surfaces were coated with IgG and that only a  small increase in fluorescence was 
seen when  the cells were incubated in vitro with  19-E12. Assuming that all of the in 
vivo  bound  surface  Ig  represented  infused  antibody  bound  to  Thy-l.1  sites,  the 
analysis of the fluorescence histograms revealed that 87 ±  4% of the available Thy-1.1 
sites had been coated with antibody in vivo. Representative results from one mouse 
are shown in the left-hand column of Fig. 5.  Further, the level of Thy-1.1  expression 
by subcutaneous  tumor cells from  treated mice, determined  by quantitative  immu- 
nofluorescence, was comparable to that seen with tumors from untreated mice. Thus, 
the growth of leukemic cells in the subcutaneous nodule occurred despite the presence 
of high levels of anti-Thy-l.1 antibody on their cell surfaces over a  prolonged period 
of time and may be attributed to a  failure of host mechanisms to eradicate antibody- 
coated leukemic cells from the subcutaneous space. 
Examination of the metastatic leukemic cells from  the spleens of treated animals 
yielded contrasting results. As shown in the right-hand column of Fig. 5, there was a 
failure to detect either surface IgG or Thy-1.1 sites after staining with a fluoresceinated 
anti-mouse IgG antibody or with  19-E12  antibody  followed by the  fluoresceinated 
anti-mouse  IgG  reagent.  A  similar  result  was  found  for  the  other  mice  in  this 
experiment. The antigenic nature of the metastatic leukemic cells in antibody-treated 
mice was  further  examined  in  an  additional  experiment.  A  lower  dose  (0.4  rag)  of 
antibody was  administered intravenously on  day 0  followed by 0.2  mg intraperito- 
neally every 3-4 d  on  a  continuous  basis. As shown  in  Fig. 6,  the infusion of lower 836  MONOCLONAL  ANTIBODY  TttERAPY  OF  MURINE  LEUKEMIA 
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Fie.  5.  Thy-1.1 antigen expression by leukemic cells from mice treated with anti-Thy- 1.1 antibody• 
AKR/J  mice were challenged subcutaneously with 3  X  10  ~ SL2  leukemic cells and treated  with 
ascites fluid containing 3.6 mg 19-E12 antibody on day 0 and  1.8 mg intraperitoneally on days 3, 
7,  11, and  14.  On day 26, when palpable  tumor nodules were  present  at  the inoculum site and 
significant spleen enlargement was apparent, individual leukemic cells were isolated fi'om the nodule 
and the spleen• Cells from the nodule (left)  and spleen (right) were incubated with 19-E12 antibody 
followed by fluorescein conjugated anti-IgG antibody (to measure unbound Thy~ 1.1 sites), fluores- 
cein conjugated anti-lgG antibody alone  (to measure in vivo binding of the infused anti-Thy-l.1 
antibody), or FITC anti-lgM  (control). Each plot represents 4,000 cells analyzed with logarithmic 
amplification. 
amounts of antibody also led to metastatic growth of cells that lacked surface Thy-1.1 
antigenic sites.  This failure to detect surface antigen was not due to blocking of the 
antigenic sites since surface IgG2a was not detected. The failure of Thy-i, I expression 
was  selective  since  surface  expression  of H-2  k and  gp70  was  maintained  at  levels 
comparable to SL2 cells  from untreated  leukemic animals.  In addition, to examine 
the possibility that only the epitope on the Thy-1 molecule detected by 19-E12 was 
not  expressed,  we  also  examined  the  leukemic  spleen  cells  using  an  anti-Thy-l.1 
alloantiserum. Again, surface binding of the anti-Thy- [. 1 serum was not detected. In 
an additional study, the intravenous infusion of even a single dose of 19-E12  (3.6 rag) 
1-2 h  after subcutaneous inoculation of 3  X  106 SL2 cells  was able  to prevent  the 
metastatic spread of leukemic cells expressing the Thy-1.1 antigen, while allowing the 
metastatic invasion of the spleen by Thy-i. I negative leukemic cells  (data not shown). 
This absence of Thy-1.1 on metastatic cells could have resulted from modulation of 
the  antigen  in  the  presence  of antibody or  from  the  selection  of antigen-negative 
variants. To differentiate these possibilities, five antigen-negative tumors were sequen- 
tially passaged five times through normal syngeneic hosts and then examined for the 
reexpression of Thy-l.1, as well  as the continued expression  of gp70. The passaged 
tumor continued to lack detectable Thy-1.1, whereas gp70 expression was maintained 
(Fig.  7).  Thus,  metastatic  disease  in  treated  mice  resulted  from  growth  of stable 
antigen-negative variants. ANTI- 
Thyl.l 
BADGER  AND  BERNSTEIN 
CONTROL  1  5 
•  (-,~:~ 
• ,~,...>.. 
~.!.~,. 
837 
ANTI- 
IgG2o 
ANTI- 
H -2  K 
I  gp70 
ANTI- 
CONV. 
ANTI- 
Thyl.I 
.:i'?::. 
m 
L  ~'. 
~:  ' ~:~iii  ..~?  m 
L/GHT SCATTER 
Flc. 6.  Antigen expression  by metastatic spleen cells. AKR/J mice were challenged with 3 X  10  6 
SL2  leukemic  ceils  subcutaneously  and  remained  untreated  or were  treated  with  ascites  fluid 
containing 0.4 mg 19-E12 antibody on day 0, and 0,2 mg i.p. twice weekly thereafter. When splenic 
enJargement  was apparent,  the metastatic  leukemic  spleen  cells  were obtained  and  incubated  in 
vitro with FITC-19-E12 (top row), FITC-rabbit anti-mouse IgG2~ antibody (second row), anti-H  -2k 
followed  by  FITC-anti-lgG (third row), anti-gp70 followed  by FITC-anti-IgG  (fourth row), o1" a 
conventional  anti-Thy-l.1  alloantiserum  followed  by  FITC-anti-lgG  (bottom  row).  Spleen cells 
from an  untreated control  and three treated animals (1, 5, and 7) are shown.  In second  box from 
top  in  the  first  column,  control  leukemic  cells  were  preincubated  with  19-E12  antibody  before 
addition  of the  anti-IgO2a-FITC  reagent.  Each  plot  represents  4,000  cells  analyzed  with  linear 
amplification. 
Discussion 
Our previously reported studies  of monoclonal antibody  therapy of transplanted 
leukemia have demonstrated the ability of antibody to cure mice challenged with up 
to 3  X  105 syngeneic  SL2  leukemia ceils  (3-5).  In the current  studies we examined 
varying antibody  regimens  and  determined  the maximal  number of leukemia cells 
present in a subcutaneous inoculum that could be eliminated by antibody. IgG2a anti- 
Thy-1.1  antibody administered as a single intravenous bolus, in doses of ascites fluid 
ranging from 0.4  to 6.4  mg of antibody or 0.5  to  16 mg of purified antibody,  could 
prevent the outgrowth of 3 X  105 SL2 leukemia cells in a portion of treated mice. The 
maximal  and  most  consistent  effect  was  achieved  by  the  infusion  of ascites  fluid 
containing 3.2 mg of antibody which cured 83% of the mice challenged with 3  X  105 
SL2  leukemia  cells.  This  relatively  high  dose  was  necessary  to  achieve  maximal 
antibody  binding  to  most  or  all  of the  target  antigen  expressed  by  subcutaneous 
tumor  cells.  Presumably,  lower  doses  were  less  effective  because  fewer  antibody 838  MONOCLONAL  ANTIBODY  THERAPY  OF  MURINE  LEUKEMIA 
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FIG.  7.  Failure of Thy-l.t  expression  by metastatic  leukemic  cells from treated  mice is due to 
emergence of stable antigen-negative variants.  Five Thy-l.l-negative leukemias  established  from 
metastatic splenic leukemic cells in mice treated with anti-Thy-l, l antibody (animals 1, 3, 4, 5, and 
7) were passaged  intraperitonealIy five times eac}~ in untreated syngeneic mice. The ability of these 
cells to reexpress the Thy 1.1 antigen was examined by incubating the cells in vitro with 19-E12 + 
FITC-anti IgG (to determine Thy- 1.1 expression), In addition, alterations in the expression of AKR- 
MuLV gp70  were examined by' staining the cells witb  16B7 followed  by FITC-anti-mouse IgG 
antibody.  Results  were  compared  with  those  obtained  with  passaged  SL2  leukemic  cells  from 
untreated mice (control)• Each plot represents  4,000 cells analyzed with linear amplification. 
molecules  fixed  to  the  tumor  cell surfaces  or because  antibody  concentrations  were 
maintained  in  the subcutaneous  space  for an  insufficient  length of time, thereby  not 
allowing for optimal  host effector activity (e.g., macrophages). 
The  highest  antibody  doses,  whether  given  in  the  form of ascites  fluid or purified 
Ig,  led  to  suboptimal  effects.  A  decrease  in  therapeutic  effects  with  supra-optimal 
doses has also been observed in other experimental  systems  (21).  It is possible that the 
inhibitory  effects  of very  high  doses  of antibody  may  result  from  the  inhibition  of BADGER AND BERNSTEIN  839 
effector cell function by high concentrations of free antibody. The occurrence of this 
phenomenon suggests the need for careful dose titrations when antibody is used for 
therapy. Although infusion of multiple doses of antibody did not prove advantageous 
in  this  study,  it  is  possible that  prolonged therapy  may be of benefit  in  situations 
where the tumor has a  longer doubling time than that of the SL2 leukemia used in 
this  study  (doubling  time <1  d).  In  those  situations,  additional  effector cells may 
localize at the tumor site and kill the antibody-coated cells before significant tumor 
growth occurs. 
The maximal number of leukemic cells that could be consistently eliminated was 
3 ×  l0  b. The results of this study identified two factors potentially responsible for this 
limitation. First, the failure of antibody to mediate the elimination of higher numbers 
of subcutaneous  tumor was shown  to result  from a  failure of the  host  to eliminate 
antibody-coated  cells.  This  failure  was  most  likely  a  consequence  of  inadequate 
participation of host effector cells. It was not due to lack of access of antibody to the 
tumor because saturation of available tumor cell surface Thy-1.1 sites in vivo by the 
infused  antibody  was  documented.  Participating  host  effector  mechanisms  have 
already been identified  as a  limiting factor in  serum therapy  (22,  23).  Presumably, 
the participating host factors consist ofeffector cells (23-25) and not lytic complement 
because the AKR/J  recipients  in  the present  experiments are deficient  in  the  fifth 
component  of complement.  It  may  also  be  argued  that  a  limiting  factor  in  this 
antibody therapy model may be that the target antigen is widely expressed by normal 
T  cells and  that  the host  effector activity against  opsonized  leukemic cells may be 
diluted by the antibody-coated lymphocytes. However, studies with both antiserum 
and monoclonal antibodies with less or no reactivity with normal cells have suggested 
that  the  maximal  antitumor  effect obtainable  with  antibody  is  the  elimination  of 
~106 cells (10,  24, 26, 27). Importantly, it has been shown that this limitation applies 
to individual sites, and that antibody treatment can prevent the growth of multiple 
implants of 105 cells in a single mouse (27). 
Although the number of antibody-coated leukemia cells which could be eliminated 
from a  subcutaneous  site was relatively small,  there are situations  where this effect 
could  prove therapeutically  useful.  In  situations  where  minimal  residual  disease  is 
present,  e.g.,  when  leukemia  in  remission,  antibody  alone  may  eliminate  the  few 
tumor cells that  remain  following conventional  therapy.  We have successfully used 
this  latter  approach  to  prolong chemotherapy-induced  remissions  in  AKR/J  mice 
with spontaneous T  cell lymphomas (5).  Where larger masses of extravascular tumor 
are involved, the potential of antibody therapy will only be realized if it is directly 
inhibitory  to tumor cells or if it  is used  as a  carrier for toxic agents.  However, the 
relative localization of antibody to tumor vs. other normal tissues must first be studied 
to determine to what extent these agents can be localized to tumor as compared with 
nonantigen-bearing target cells. 
The second factor found  to limit antibody therapy was the emergence of variant 
leukemic cells that did not express the target Thy-1.1 antigen. Antibody was, however, 
highly effective in  eliminating antigen-positive metastasizing cells and significantly 
delayed the occurrence of metastatic disease and  death.  Even when relatively large 
doses  of  tumor  cells  and  therapeutically  suboptimal  amounts  of  antibody  were 
administered, antibody therapy completely prevented the spread of Thy-1.1-bearing 
tumor cells. This effect most likely resulted  from the efficient removal of antibody- 840  MONOCLONAL ANTIBODY THERAPY OF  MURINE LEUKEMIA 
coated cells by the reticuloendothelial system. Alternatively, it is possible that surface 
antibody prevented tumor cells  from establishing themselves at an appropriate site. 
The problem of the emergence of antigen-negative variants  as observed in  these 
studies potentially can be overcome by using combinations of antibodies directed at 
different  antigens,  because  the  frequency  of  variants  lacking  multiple  unrelated 
determinants should be vastly reduced from that of variants lacking only one antigen. 
The effectiveness of antibody in preventing metastatic disease also suggests that the 
infusion of antibody during complete or partial resection of solid tumor masses may 
prove useful  in  preventing hematogenous dissemination  of malignant cells that  are 
shed during surgery. 
Summary 
The ability of monoclonal antibodies against the Thy-1.1 differentiation antigen to 
inhibit  the  growth of transplanted  syngeneic AKR/J  SL2  leukemic cells  has  been 
previously  demonstrated.  In  the  present  study  we  further  examined  therapy  with 
monoclonal  antibody  of the  IgG2a  isotype,  which  was  the  most  effective  isotype 
studied. Intravenous infusion of ascites fluid containing the anti-Thy-1.1 monoclonal 
antibody 19-E12  1  2 h after tumor implantation led to inhibition of the growth of 3 
X  105 but not 3 X  106 syngeneic SL2 leukemic cells. The achievement of the maximal 
therapeutic  effect  required  the  infusion  of a  dose  containing  3.2  mg of antibody, 
which inhibited the growth of a subcutaneous inoculum of 3 X  105 SL2 leukemic cells 
in  83%  of treated  mice.  Multiple  doses  of antibody were  no more effective than  a 
single dose given shortly after tumor implantation. The infusion of this relatively large 
3.2-mg dose of antibody was required to infiltrate the subcutaneous space and saturate 
surface Thy-1.1 sites on leukemic cells  in a subcutaneous tumor nodule. 
The failure of antibody to inhibit  larger numbers of tumor cells  was investigated. 
Growth of a subcutaneous tumor nodule in mice challenged with more than 3 X  l0  s 
ceils  resulted from the growth of Thy-1. I-bearing cells  in spite of the presence of the 
infused  anti-Thy-l.1  antibody on their surfaces.  In contrast,  metastatic growth was 
due  to  the emergence of variant  leukemic cells  lacking the Thy-l.1  antigen.  Thus, 
treatment  of transplanted  T  leukemic cells  with  an  IgG2a anti-Thy-l.1  monoclonal 
antibody was effective in eliminating 3 ×  l0  s antigen-bearing leukemic cells from the 
subcutaneous space and was very effective in preventing metastasis of leukemic cells 
expressing  the  target  Thy-l.1  antigen.  Therapy  was  limited  by the  failure  of host 
mechanisms to eliminate larger numbers of subcutaneous leukemic cells  coated with 
the infused antibody and by the emergence of variant leukemic cells lacking the target 
antigen. 
Received  for publication 19 May  1982 and in revised  form 3 November 1982. 
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